Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Depreciation & Amortization (CF) (2016 - 2025)

Adma Biologics (ADMA) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 5.25% year-over-year to $2.0 million, compared with a TTM value of $8.1 million through Dec 2025, up 0.63%, and an annual FY2025 reading of $8.1 million, up 0.63% over the prior year.
  • Depreciation & Amortization (CF) was $2.0 million for Q4 2025 at Adma Biologics, up from $2.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q1 2024 and bottomed at $1.2 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.9 million, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 55.88% in 2021, then dropped 7.82% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then grew by 27.55% to $1.9 million in 2022, then rose by 8.91% to $2.1 million in 2023, then decreased by 7.82% to $1.9 million in 2024, then grew by 5.25% to $2.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for ADMA at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.1 million in Q2 2025.